Mesa Laboratories, Inc. MLAB
134.04
(3.46)
(2.52%)
as of 25 Sep
- Market cap
- $769.4M
- P/E
- 156×
Follow MLAB
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
115.76 | 71.89 | 117.16 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.26 | 1.96 | 1.75 | 1.51 | |
P/FCF ratio |
10.65 | 12.32 | 11.44 | 9.92 | |
P/Operating CF |
38.22 | 34.92 | 23.16 | 44.92 | |
P/B ratio |
2.98 | 2.62 | 2.33 | 2.07 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.70 | 2.46 | 2.31 | 2.14 | |
EV/EBITDA |
14.86 | 14.65 | 13.70 | 13.15 | |
EV/Operating CF |
12.13 | 14.29 | 13.76 | 12.80 | |
EV/FCF |
12.77 | 15.46 | 15.06 | 14.07 | |
Quick Ratio |
1.14 | 1.15 | 1.27 | 1.25 | |
Current Ratio |
1.79 | 1.72 | 1.94 | 2.02 | |
Net Debt/EBITDA |
8.85 | 5.65 | 868.05 | 14.61 | |
Debt/Assets |
34.08% | 35.41% | 38.20% | 40.63% | |
Debt/Equity |
0.76 | 0.81 | 0.89 | 0.98 | |
Asset Turnover |
0.58 | 0.58 | 0.57 | 0.55 | |
Operating CF/Net income |
5.21 | (3.38) | 5.17 | 3.32 | |
Capex/Depreciation |
(0.10) | (0.02) | 0.09 | (0.19) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
7.86% | 8.23% | 7.72% | 8.31% | |
Selling, General and Administrative Expense of Revenue |
45.32% | 53.68% | 44.21% | 45.37% | |
Intangible Assets out of Total Assets |
0.63 | 0.63 | 0.64 | 0.65 | |
Share Based Compensation of Revenue |
3.92% | 10.66% | 5.19% | 6.28% | |
Graham Net Nets |
(0.23) | (0.28) | (0.33) | (0.42) | |
Graham Number |
25.41 | 30.57 | 22.56 | 0.00 | |
Earnings Yield |
0.86% | 1.39% | 0.85% | (0.45%) | |
Free Cash Flow Yield |
9.39% | 8.12% | 8.74% | 10.08% | |
Revenue per Share |
10.63 | 11.56 | 11.77 | 11.02 | |
Operating CF per Share |
2.60 | 2.53 | 3.39 | 1.49 | |
Capex per Share |
(0.10) | (0.08) | (0.13) | (0.20) | |
Free Cash Flow per Share |
2.51 | 2.46 | 3.26 | 1.29 | |
Cash per Share |
5.43 | 4.88 | 5.24 | 3.71 | |
Shareholders Equity per Share |
33.37 | 33.78 | 33.75 | 32.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.37 | 33.78 | 33.75 | 32.38 | |
Free Cash Flow |
14.18 | 13.55 | 18.02 | 7.13 | |
Working Capital |
45.53 | 44.37 | 51.24 | 49.14 | |
Capital Expenditures |
(0.56) | (0.42) | (0.73) | (1.09) | |
Net Current Asset Value |
(127.62) | (135.23) | (142.53) | (154.45) | |
EV/EBIT |
30.04 | 33.07 | 33.16 | 34.84 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 | |
Net Profit Margin |
4.71% | (6.49%) | 5.57% | 4.08% | |
Price to Operating Income |
25.05 | 26.34 | 25.20 | 24.57 | |
| Other line items | |||||
Average Receivables |
36.74 | 43.03 | 39.44 | 40.16 | |
Average Payables |
6.86 | 5.34 | 4.67 | 5.54 | |
Average Inventory |
27.67 | 25.87 | 27.34 | 28.74 | |
Average Assets |
427.48 | 430.55 | 436.00 | 442.22 | |
Average Common Equity |
180.63 | 173.04 | 170.95 | 169.96 |
Columns are period end dates